Market Overview:
The global motor neuron diseases treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of motor neuron diseases, rising awareness about available treatments, and growing demand for better and innovative therapies. Based on type, the market is segmented into riluzole, nusinersen, physical therapy, respiratory therapy, and others. Riluzole is the most commonly used drug for treating motor neuron diseases and held a dominant share of the market in 2017. However, nusinersen is expected to grow at a higher CAGR during the forecast period as it offers better outcomes than other drugs available in the market. Based on application, multidisciplinary clinics accounted for majority of the share in 2017 owing to rising demand for comprehensive care for patients with motor neuron diseases.
Product Definition:
Motor neuron diseases treatment is a therapy that is used to help improve the quality of life for those who are affected by motor neuron diseases. It can help to improve muscle function and reduce the symptoms of the disease.
Riluzole:
Riluzole (Rilutek) is an anti-neuronotic drug developed by Ciba Pharmaceuticals. It was first approved in Japan in 1995 for the treatment of amyotrophic lateral sclerosis and in 1996 for the U.S. market, under the brand name Rilutek.
Nusinersen:
Nusinersen is a drug that is under clinical investigation for the treatment of spinal and brain motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and dementia. The company has applied for Nusinersen to be designated as a breakthrough therapy with an aim to expedite its approval by the U.S. FDA and entry into the market in near future.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to an increase in demand for rehabilitation services after a stroke or spinal cord injury. The multidisciplinary clinics are also expected to witness lucrative growth over the forecast period owing to increasing awareness about recovery and rehabilitation time. These facilities provide treatment options for patients with motor neuron diseases, such as physical therapy, occupational therapy, speech & language pathology and neuropsychology services along with medical management of these conditions.
Hospitals are expected to be one of the fastest-growing segments during the forecast period owing to rising healthcare costs across various countries worldwide coupled with growing investments by governments in improving healthcare infrastructure at a local level. Furthermore, hospitals offer specialized care facilities that focus on treating patients suffering from neurological disorders including multiple sclerosis and Parkinson's disease which further boosts revenue generation capacity annually within this segment globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high disposable income, and favorable reimbursement policies & regulatory approvals. The U.S., which is at the forefront of this region, has a well-developed healthcare infrastructure and also happens to be one of the most developed economies in terms of research activities as well as drug development practices across all industries.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as rising disposable income coupled with increasing awareness levels pertaining towards available treatment options for various neurological disorders among patients & their families; supportive government initiatives; and availability & adoption of advanced therapies for motor neuron diseases treatment in countries like China & India that lack proper medical infrastructure but have skilled neurosurgeons who are highly competent at treating these conditions successfully with relatively crude tools (physical therapy devices).
Growth Factors:
- Increasing incidence of motor neuron diseases (MND)
- Growing awareness about MND and its treatment options
- Rising demand for better and more effective treatments for MND
- Availability of government funding for research on MND treatments
- Technological advancements in the field of MND treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Motor Neuron Diseases Treatment Market Research Report
By Type
Riluzole, Nusinersen, Physical Therapy, Respiratory Therapy, Others
By Application
Multidisciplinary Clinics, Hospitals, Social Work Facilities, Others
By Companies
NIH, UCL Institute of Neurology, National Neuroscience Institute, The University of Melbourne, The University of Sheffield, OZBiosciences, The University of Queensland, MND Australia
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Motor Neuron Diseases Treatment Market Report Segments:
The global Motor Neuron Diseases Treatment market is segmented on the basis of:
Types
Riluzole, Nusinersen, Physical Therapy, Respiratory Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multidisciplinary Clinics, Hospitals, Social Work Facilities, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- NIH
- UCL Institute of Neurology
- National Neuroscience Institute
- The University of Melbourne
- The University of Sheffield
- OZBiosciences
- The University of Queensland
- MND Australia
Highlights of The Motor Neuron Diseases Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Riluzole
- Nusinersen
- Physical Therapy
- Respiratory Therapy
- Others
- By Application:
- Multidisciplinary Clinics
- Hospitals
- Social Work Facilities
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Motor Neuron Diseases Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for motor neuron diseases, but treatments can help improve the symptoms. Treatment options may include medication, surgery, and physical therapy.
Some of the key players operating in the motor neuron diseases treatment market are NIH, UCL Institute of Neurology, National Neuroscience Institute, The University of Melbourne, The University of Sheffield, OZBiosciences, The University of Queensland, MND Australia.
The motor neuron diseases treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Motor Neuron Diseases Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Motor Neuron Diseases Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Motor Neuron Diseases Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Motor Neuron Diseases Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Motor Neuron Diseases Treatment Market Size & Forecast, 2020-2028
4.5.1 Motor Neuron Diseases Treatment Market Size and Y-o-Y Growth
4.5.2 Motor Neuron Diseases Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Riluzole
5.2.2 Nusinersen
5.2.3 Physical Therapy
5.2.4 Respiratory Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Multidisciplinary Clinics
6.2.2 Hospitals
6.2.3 Social Work Facilities
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Motor Neuron Diseases Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Motor Neuron Diseases Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Riluzole
9.6.2 Nusinersen
9.6.3 Physical Therapy
9.6.4 Respiratory Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Multidisciplinary Clinics
9.10.2 Hospitals
9.10.3 Social Work Facilities
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Riluzole
10.6.2 Nusinersen
10.6.3 Physical Therapy
10.6.4 Respiratory Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Multidisciplinary Clinics
10.10.2 Hospitals
10.10.3 Social Work Facilities
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Riluzole
11.6.2 Nusinersen
11.6.3 Physical Therapy
11.6.4 Respiratory Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Multidisciplinary Clinics
11.10.2 Hospitals
11.10.3 Social Work Facilities
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Riluzole
12.6.2 Nusinersen
12.6.3 Physical Therapy
12.6.4 Respiratory Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Multidisciplinary Clinics
12.10.2 Hospitals
12.10.3 Social Work Facilities
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Riluzole
13.6.2 Nusinersen
13.6.3 Physical Therapy
13.6.4 Respiratory Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Multidisciplinary Clinics
13.10.2 Hospitals
13.10.3 Social Work Facilities
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Motor Neuron Diseases Treatment Market: Competitive Dashboard
14.2 Global Motor Neuron Diseases Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 NIH
14.3.2 UCL Institute of Neurology
14.3.3 National Neuroscience Institute
14.3.4 The University of Melbourne
14.3.5 The University of Sheffield
14.3.6 OZBiosciences
14.3.7 The University of Queensland
14.3.8 MND Australia
